NR3C2 and diabetic kidney disease: The minerAlocorticoid Receptor antagonist Tolerability Study-Diabetic Nephropathy (ARTS-DN) was a randomized, double-blind, placebo-controlled, phase 2b study on 823 type 2 DM patients with albuminuria (UACR ≥ 30 mg/g), an eGFR higher than 30 mL/min/1.73 m2, being treated with at least the minimum recommended dosage of a RAS inhibitor before the screening visit and with a serum potassium concentration ≤ 4.8 mmol/L [131].